Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dopaminergic neurons are cells that produce and release dopamine, and the nigrostriatal pathway is the neural pathway connecting the substantia nigra pars compacta to the striatum. This query presents a conceptual issue as it describes a neuronal population and neural circuit, not a discrete therapeutic target molecule or receptor suitable for drug development. While these neurons are critically involved in motor control, they are cellular structures rather than individual receptor, enzyme, or transporter molecules that can be directly targeted by drugs. The substantia nigra pars compacta is the specific brain region containing the dopaminergic neurons that form the nigrostriatal pathway. These neurons project dopaminergically to the striatum via the nigrostriatal pathway, where dopamine acts on D1 and D2 dopamine receptors expressed on striatal neurons. The pathway is clinically significant because loss of dopaminergic neurons in this region causes Parkinson's disease. Actual therapeutic targets related to this system would be specific molecular entities such as dopamine receptors, the dopamine transporter, or dopamine itself.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dopaminergic Neurons in the Nigrostriatal Pathway.